Terms: = Leukemia AND CARS, P49589, 833, ENSG00000110619 AND Prognosis
31 results:
1. Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
Acharya L; Garg A; Rai M; Kshetri R; Grewal US; Dhakal P
J Investig Med; 2024 Jan; 72(1):32-46. PubMed ID: 37497999
[TBL] [Abstract] [Full Text] [Related]
2. Association between
Vu MP; Nguyen CN; Vu H; Nguyen TM; Nguyen TT; Pham PT
J Int Med Res; 2022 Dec; 50(12):3000605221138490. PubMed ID: 36539954
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Applications of Flow Cytometry in Cancer Immunotherapies: From Diagnosis to Treatments.
Mishra HK
Methods Mol Biol; 2023; 2593():93-112. PubMed ID: 36513926
[TBL] [Abstract] [Full Text] [Related]
4. CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis.
Yin Z; Lin Y; Liu D; Tong C; Liu S
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1706. PubMed ID: 35995579
[TBL] [Abstract] [Full Text] [Related]
5. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
Caballero AC; Escribà-Garcia L; Alvarez-Fernández C; Briones J
Front Immunol; 2022; 13():904497. PubMed ID: 35874685
[TBL] [Abstract] [Full Text] [Related]
6. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia.
Senjo H; Onozawa M; Hidaka D; Yokoyama S; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Hashimoto D; Kondo T; Teshima T
Sci Rep; 2022 May; 12(1):8885. PubMed ID: 35614177
[TBL] [Abstract] [Full Text] [Related]
7. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract] [Full Text] [Related]
8. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract] [Full Text] [Related]
9. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract] [Full Text] [Related]
10. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic leukemia.
Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
[TBL] [Abstract] [Full Text] [Related]
11. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract] [Full Text] [Related]
13. Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic leukemia.
Liu J; Tan X; Ma YY; Liu Y; Gao L; Gao L; Kong P; Peng XG; Zhang X; Zhang C
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e349-e358. PubMed ID: 31076372
[TBL] [Abstract] [Full Text] [Related]
14. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Thomas X; Paubelle E
Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
[TBL] [Abstract] [Full Text] [Related]
15. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract] [Full Text] [Related]
16. Glycan-directed CAR-T cells.
Steentoft C; Migliorini D; King TR; Mandel U; June CH; Posey AD
Glycobiology; 2018 Sep; 28(9):656-669. PubMed ID: 29370379
[TBL] [Abstract] [Full Text] [Related]
17. [The analysis of prognosis-associated factors in adults with acute promyelocytic leukemia].
Ma RJ; Zhu ZM; Yuan XL; Jiang L; Yang SW; Yang J; Guo JM; Shi J; Lei PC; Zhang L; Shang BJ; Sun K; Zhai YP; Li W; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):592-596. PubMed ID: 28810326
[No Abstract] [Full Text] [Related]
18. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
[TBL] [Abstract] [Full Text] [Related]
19. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
[TBL] [Abstract] [Full Text] [Related]
20. Hemorrhagic Cystitis Requiring Bladder Irrigation is Associated with Poor Mortality in Hospitalized Stem Cell Transplant Patients.
Raup VT; Potretzke AM; Manley BJ; Brockman JA; Bhayani SB
Int Braz J Urol; 2015; 41(6):1126-31. PubMed ID: 26742970
[TBL] [Abstract] [Full Text] [Related]
[Next]
